26.84
Alkermes Plc stock is traded at $26.84, with a volume of 93,763.
It is down -1.29% in the last 24 hours and down -8.55% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$27.19
Open:
$27
24h Volume:
93,763
Relative Volume:
0.05
Market Cap:
$4.43B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
13.76
EPS:
1.95
Net Cash Flow:
$315.22M
1W Performance:
-8.58%
1M Performance:
-8.55%
6M Performance:
-13.95%
1Y Performance:
+1.24%
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ALKS
Alkermes Plc
|
26.84 | 4.46B | 1.51B | 333.35M | 315.22M | 1.95 |
![]()
ZTS
Zoetis Inc
|
153.64 | 67.31B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.75 | 45.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
HLN
Haleon Plc Adr
|
9.945 | 43.35B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.46 | 18.68B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
304.07 | 13.44B | 2.99B | 1.21B | 1.13B | 25.06 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-15-25 | Initiated | Goldman | Buy |
Jun-17-25 | Upgrade | UBS | Neutral → Buy |
May-28-25 | Initiated | Needham | Buy |
Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
Mar-04-25 | Upgrade | UBS | Sell → Neutral |
Feb-11-25 | Initiated | Deutsche Bank | Buy |
Nov-05-24 | Upgrade | Stifel | Hold → Buy |
Jun-17-24 | Initiated | TD Cowen | Buy |
Mar-19-24 | Initiated | Robert W. Baird | Outperform |
Feb-20-24 | Downgrade | UBS | Neutral → Sell |
Nov-20-23 | Resumed | JP Morgan | Neutral |
Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
Oct-17-23 | Initiated | UBS | Neutral |
Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
Aug-16-22 | Initiated | Piper Sandler | Neutral |
Apr-22-22 | Resumed | Goldman | Buy |
Apr-20-22 | Initiated | Goldman | Buy |
Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
Dec-01-21 | Initiated | Citigroup | Neutral |
Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
Feb-06-20 | Initiated | Mizuho | Neutral |
Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
May-31-19 | Initiated | H.C. Wainwright | Neutral |
May-01-19 | Downgrade | Citigroup | Buy → Neutral |
Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
Dec-14-18 | Initiated | Wolfe Research | Underperform |
Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
Nov-05-18 | Initiated | Piper Jaffray | Neutral |
Aug-07-18 | Initiated | Stifel | Hold |
Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
May-16-18 | Upgrade | Citigroup | Neutral → Buy |
May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
Abivax’s miRNA therapy emerges as a new mechanism for ulcerative colitis - biocentury.com
Goldman Sachs Initiates Alkermes (ALKS) with a Buy Rating - MSN
What analysts say about Alkermes plc stockHigh-yield portfolio picks - Autocar Professional
Alkermes plc (NASDAQ:ALKS) Launches Phase II Trial of ALKS 2680 for Idiopathic Hypersomnia - MSN
Alkermes plc Stock Analysis and ForecastSuperior investment outcomes - jammulinksnews.com
What drives Alkermes plc stock priceConsistently exceptional gains - Autocar Professional
Is Alkermes plc a good long term investmentFree Wealth Planning Blueprint - jammulinksnews.com
Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study - Yahoo Finance
Alkermes Announces Positive Phase 2 Study Results - TipRanks
Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results - insights.citeline.com
Jefferies Raises Target for Alkermes (ALKS) Following Promising Drug Data | ALKS Stock News - GuruFocus
Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives. - inkl
Alkermes Oral Drug Helps Patients Stay Awake In Mid-Stage Sleep Disorder Study - inkl
Alkermes narcolepsy drug headed for late-stage testing - BioPharma Dive
Needham & Company LLC Reaffirms Buy Rating for Alkermes (NASDAQ:ALKS) - MarketBeat
Alkermes stock rating reiterated as Buy by Stifel after positive narcolepsy data - Investing.com UK
Alkermes Vibrance-1 Phase 2 Study Of Alixorexton In Narcolepsy Type 1 Meets Primary Goal - Nasdaq
Alkermes announces positive topline results from Vibrance-1 Phase 2 study - MarketScreener
Alkermes narcolepsy drug shows positive results in phase 2 trial By Investing.com - Investing.com UK
Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 - PR Newswire
Is Alkermes Plc's (NASDAQ:ALKS) Latest Stock Performance Being Led By Its Strong Fundamentals? - 富途牛牛
10 Most Undervalued Pharma Stocks To Buy Now - Insider Monkey
BlackRock increases stake in Alkermes to 17.05% By Investing.com - Investing.com India
BlackRock increases stake in Alkermes to 17.05% - Investing.com
Alkermes to Release Q2 Financial Results on July 29, 2025 - AInvest
Alkermes to Report Second Quarter Financial Results on July 29, 2025 - MarketScreener
Expert Outlook: Alkermes Through The Eyes Of 6 Analysts - Benzinga
Goldman Sachs Initiates Coverage on Alkermes (ALKS) with a Buy R - GuruFocus
How Much Upside is Left in Alkermes (ALKS)? Wall Street Analysts Think 33.19% - Yahoo Finance
(ALKS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Alkermes (NASDAQ:ALKS) shareholders have earned a 9.3% CAGR over the last five years - simplywall.st
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018ALKS - ACCESS Newswire
Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore - Yahoo Finance
Alkermes plc(NasdaqGS: ALKS) added to Russell 2500 Value Index - MarketScreener
Alkermes spinoff Mural plunges on plans to halt ovarian cancer trial - MSN
(ALKS) On The My Stocks Page - news.stocktradersdaily.com
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alkermes Plc Stock (ALKS) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Nichols Christian Todd | SVP, Chief Commercial Officer |
Jun 10 '25 |
Sale |
31.09 |
3,334 |
103,654 |
86,208 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):